focus -WSS

focus

author：knowledge 2025-10-02 00:19:22 - browse：67

Have you ever taken phenylephrine for a stuffed-up nose and then felt better? If so, you might have been perplexed when Food and Drug Administration experts recently said that that the drug — which is in some versions of DayQuil, Sudafed, and other medicines — is no more effective than a placebo.

But to Michael H. Bernstein, an assistant professor of diagnostic imaging at the Warren Alpert Medical School of Brown University, it all makes sense. Bernstein says that “no better than a placebo” still means that it works, sort of. “If we expect to feel better, then we probably will,” he told me. And that complicates the idea of what medical treatment “works.”

On this episode of the “First Opinion Podcast,” we discuss the placebo effect and its counterpart, the “nocebo effect” — if you tell patients something will make them feel worse, it generally comes true. “You’re better off hearing from a doctor something to the effect of 3 out of 4 patients who take this drug have no side effects at all versus 25% of people who take this drug do get side effects,” he said.

Bernstein also shared the delightful story of how he got into the “medical expectations” field, which started with an experiment in which he had to convince underage students that they were drinking alcohol when they weren’t.

Our conversation was based on a First Opinion Bernstein recently wrote with Grayson L. Baird, “Phenylephrine is no better than a placebo. What if that’s still better than nothing?”

Be sure to sign up for the weekly “First Opinion Podcast” on Apple Podcasts, Spotify, Google Play, or wherever you get your podcasts.

Previous article： How to save PrEP access — and even expand it
Next article： Readout LOUD podcast: Biotech layoffs, stock slump, 2024 preview

hotspot

WSS

Medicare threatens to cut off funding for HCA's Mission hospital

Gilead’s Trodelvy fails in lung cancer, raises questions on ADCs

Eli Lilly, Pfizer, and others want in on the online prescription market

Vaccine advisory panel ACIP left half staffed by HHS

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Prior authorization will have to move faster under new Biden rule

Wikipedia

focus

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

NIH director takes cautious approach to Biden drug pricing priority

Alkermes shareholders re

Copay coupons to count toward deductibles, after Biden court move

Anesthesiologist group: stop taking Ozempic before surgery

A ‘polypill’ could sharply reduce cardiovascular disease in the U.S.

Medicare details structure of new drug price negotiation program

FDA clears AI tool for detecting skin cancer

Supreme Court strikes down use of affirmative action

KalVista pill reduced swelling 'attacks' caused by genetic disease

explore

Medicare threatens to cut off funding for HCA's Mission hospital

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

Why did Pfizer dish out millions for a Super Bowl ad?

Parkinson’s finding may lead to tests and, someday, treatments

Gilead acquiring CymaBay and its liver disease drug for $4.3 billion

New brain studies show LSD's effects on the brain in full color

hotspot

explore

hotspot

entertainment